Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (16226)	7/8/2003 5:24:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Excellent, Baxter was long proven inept (including other products with other smaller biotechs). Bpieye with the Joslin must be a priority. 2nd Bpi as antibiotic against resistant strains in non shock situations. 3rd bpi for septic shock, but following the Lilly Xigris approach to the trial, a candidates line waiting for the immediate onset of shock in already hospitalized subjects, not the ER.

To: Arthur Radley who wrote (16226)	7/9/2003 4:11:11 PM
From: Edscharp	Read Replies (1) \| Respond to of 17367

Tex, Interesting article. You have to wonder about the perceived efficacy of neuprex if Baxter is willing to pay $10M to get it off their books. On the other, this is a brilliant coup for Xoma. Squeezing $10M+ out of Baxter is probably the biggest return anybody has ever gotten for a failed drug. A hearty congratulations to Xoma management is in order. This is a brilliant concept. Why worry about making approvable efficacious drugs when there is good money to be made on the non-approvable variety? I believe this new philosophy may turn the biotech world upside down. <g>